Dose-response Study of OPC-12759 Ophthalmic Suspension

Summary

The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.

Timeline

Start

2005-01

Primary completion

2006-04

Completion

2007-03

Outcome

Missed primary endpoint

registry analysis (superiority or other test); 0.5% OPC-12759 vs 1% OPC-12759 vs 2% OPC-12759 vs Placebo; p = 0.385; t-test, 2 sided; note: versus placebo NCT00234078 ↗

registry analysis (superiority or other test); 0.5% OPC-12759 vs 1% OPC-12759 vs 2% OPC-12759 vs Placebo; p = 0.601; t-test, 2 sided; note: versus placebo NCT00234078 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rebamipide	Small molecule	0.5 %	—
Subject	Rebamipide	Small molecule	1 %	—
Subject	Rebamipide	Small molecule	2 %	—

Indications